Drug Trial News RSS Feed - Drug Trial News

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases... [More]
Monash University researcher helps identify right type of Ebola vaccine trial

Monash University researcher helps identify right type of Ebola vaccine trial

An Australian researcher has helped identify the kind of human trial that is most effective for testing Ebola vaccines. [More]
Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. [More]
Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant efficacy in treating opioid-induced constipation (OIC) in patients with chronic non-cancer pain. [More]
vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease. [More]
Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease). [More]
Combined therapy shows promise in cystic fibrosis patients

Combined therapy shows promise in cystic fibrosis patients

Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase III international clinical trial published online in the New England Journal of Medicine on May 17, 2015. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Drug combination lengthens lives of metastatic colorectal cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments. [More]
Results from four major studies on cancer treatments to be presented at ASCO Annual Meeting

Results from four major studies on cancer treatments to be presented at ASCO Annual Meeting

The American Society of Clinical Oncology today announced results from four major studies to be presented at ASCO's 51st Annual Meeting, May 29-June 2, in Chicago. Findings showed that use of a widely available vitamin pill reduces the risk of non-melanoma skin cancers; that early chemotherapy extends the lives of men with advanced prostate cancers; and that new therapies can improve outcomes for children with a rare form of kidney cancer and adults with relapsed multiple myeloma. [More]
Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer. [More]
Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology. [More]
Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation. [More]
TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB). It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB. [More]

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50... [More]
Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1. [More]
Orthocell’s Ortho-ATI therapy improves clinical outcomes in patients with tennis elbow degeneration

Orthocell’s Ortho-ATI therapy improves clinical outcomes in patients with tennis elbow degeneration

Regenerative medicine company Orthocell Limited is pleased to announce positive 3-5 year data from a study of its tendon cell treatment for tennis elbow has been presented at the International Cartilage Repair Society annual scientific meeting. [More]
Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells. [More]
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options. [More]
Advertisement
Advertisement